The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to McGuire et al., N Engl J Med 334(1):1-6 January 4, 1996.

Correspondence
PreviousPrevious
Volume 334:1268-1270 May 9, 1996 Number 19
NextNext

Chemotherapy for Ovarian Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by McGuire, W. P.
-Related Article
by McGuire, W. P.
-PubMed Citation
To the Editor: As reported by McGuire et al. (Jan. 4 issue),1 the results of the Gynecologic Oncology Group's phase 3 trial comparing paclitaxel plus cisplatin with cyclophosphamide plus cisplatin in women with ovarian cancer are exciting and encouraging. However, the data from this trial need to be interpreted with caution, for a number of reasons.

First, there is increasing evidence that the patients in the control group may not have received the best available platinum-based treatment. McGuire et al. state, "It appears that the relative benefit of paclitaxel in our trial was not due to a poorer-than-anticipated outcome" in . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.